Ferumoxytol for treating iron deficiency anemia in CKD

Journal of the American Society of Nephrology

Volumn 19, Issue 8, 2008, Pages 1599-1605

  Spinowitz, Bruce S ^a   Kausz, Annamaria T ^b,c,h   Baptista, Jovanna ^b   Noble, Sylvia D ^d   Sothinathan, Renuka ^e   Bernardo, Marializa V ^f   Brenner, Louis ^b,g   Pereira, Brian J G ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b AMAG PHARMACEUTICALS INC   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d Northwest Louisiana Nephrology   (United States)

^e Clinical Research and Consulting Center   (United States)

^f Southwest Houston Research   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCUSATE SODIUM; DOCUSATE SODIUM PLUS FERROUS FUMARATE; ERYTHROPOIETIN; FERRO SEQUELS; FERROUS FUMARATE; FERUMOXYTOL; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; UNCLASSIFIED DRUG; IRON; MAGNETITE; TRACE ELEMENT;

ADULT; AGED; ARTICLE; CHILL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INCREASED APPETITE; INJECTION SITE SWELLING; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; CHRONIC KIDNEY FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANEMIA, IRON-DEFICIENCY; FEMALE; FERROSOFERRIC OXIDE; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TRACE ELEMENTS;

EID: 49649099818     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007101156     Document Type: Article

References (52)

1. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ: Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10: 1793-1800, 1999
2. Hsu CY, McCulloch CE, Curhan GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13: 2783-2786, 2002
3. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162: 1401-1408, 2002
4. Harnett JD, Kent GM, Foley RN, Parfrey PS: Cardiac function and hematocrit level. Am J Kidney Dis 25: S3-S7, 1995
5. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300: 573-578, 1990
6. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19: 161-167, 2006
7. Mafra D, Cuppari L, Cozzolino SM: Iron and zinc status of patients with chronic renal failure who are not on dialysis. J Ren Nutr 12: 38-41, 2002
8. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26: 292-299, 1995
9. Post JB, Wilkes BM, Michelis MF: Iron deficiency in patients with chronic kidney disease: Potential role for intravenous iron therapy independent of erythropoietin. Int Urol Nephrol 38: 719-723, 2006
10. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29: 319-333, 1997
11. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13: 82-88, 1998
12. Akmal M, Sawelson S, Karubian F, Gadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42: 198-202, 1994
13. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148, 1989
14. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM: Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 54: 877-884, 1979
15. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S11-S15, 2006
16. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 Suppl 2: ii1-ii47, 2004
17. Kaltwasser JP, Hansen C, Oebike Y, Werner E: Assessment of iron availability using stable 54Fe. Eur J Clin Invest 21: 436-442, 1991
18. Macdougall IC: Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 69: S61-S66, 1999
19. Nielsen P, Kongi R, Buggisch P, Fischer R: Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia: Therapeutic efficacy of iron(II)-glycine sulfate. Arzneimittelforschung 55: 376-381, 2005
20. Using iron agents: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S58-S70, 2006
21. Venofer [package insert], Shirley, NY, American Regent, Inc., 2005
22. Ferrlecit [package insert], Corona, CA, Watson Pharma, Inc., 2006
23. Dexferrum [package insert], Shirley, NY, American Regent Laboratories, Inc., 2001
24. INFeD Prescribing Information, Morristown, NJ, Watson Pharma, Inc., 2001
25. Fishbane S: Safety in iron management. Am J Kidney Dis 41: 18-26, 2003
26. Hamstra RD, Block MH, Schocket AL: Intravenous iron dextran in clinical medicine. JAMA 243: 1726-1731, 1980
27. Fletes R, Lazarus JM, Gage J, Chertow GM: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37: 743-749, 2001
28. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61: 1830-1839, 2002
29. Bailie GR, Clark JA, Lane CE, Lane PL: Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 20: 1443-1449, 2005
30. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21: 378-382, 2006
31. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38: 988-991, 2001
32. Charytan C, Qunibi W, Bailie GR: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100: c55-c62, 2005
33. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68: 2846-2856, 2005
34. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ: Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 38: 803-812, 2001
35. Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 21: 290-295, 2001
36. Silverberg DS, Blum M, Agbaria Z, Schwartz D, Zubkov A, Yachnin T, Iaina A: Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 69: S79-S85, 1999
37. Data on file, AMAG Pharmaceuticals, Inc., Cambridge, MA, 2004
38. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK: Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 25: 400-410, 2005
39. Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, Galler M: The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 68: 1801-1807, 2005
40. 59Fe-labeled ferumoxytol into red blood cells following intravenous (IV) administration in rats [Abstract]. J Am Soc Nephrol 18: 289A, 2007
41. Patient Characteristics: USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007, pp 99-110
42. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, Pereira BJ: Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 12: 1501-1507, 2001
43. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A: A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26: 445-454, 2006
44. Sepandj F, Jindal K, West M, Hirsch D: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11: 319-322, 1996
45. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000
46. FDA Public Health Advisory: Erythropoiesis Stimulating Agents (ESAs), Washington, DC, US Food and Drug Administration, Center for Drug Evaluation and Research, 2007
47. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
48. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
49. Macdougall IC, Roche A: Administration of intravenous iron sucrose as a 2-minute push to CKD patients: A prospective evaluation of 2,297 injections. Am J Kidney Dis 46: 283-289, 2005
50. NKF-KDOQI: Clinical practice guidelines for vascular access. Am J Kidney Dis 48: S176-S247, S288-S306, 2006
51. St Peter WL, Lambrecht LJ, Macres M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28: 523-528, 1996
52. Clinical Trials.Gov. Bethesda, National Institutes of Health, 2005